Abstract:A critical issue in understanding Huntington's disease (HD) pathogenesis is how the ubiquitously expressed mutant huntingtin (mhtt) with an expanded polyglutamine repeat can cause selective toxicity of striatal and cortical neurons. Two potential cellular models may contribute to such specificity: expression of mhtt in these vulnerable neurons alone may be sufficient to result in their dysfunction and/or degeneration (cell-autonomous model); or mhtt in other cell types can elicit pathological cell-cell interactions to cause the vulnerable neurons to become dysfunctional and be at risk for degeneration (cell-cell interaction model). To distinguish between these two models, we have selectively expressed a neuropathogenic fragment of mhtt-exon1 in striatal medium spiny neurons (MSNs) by crossing a conditional mouse model of HD with a striatal-specific Cre mouse line. In this striatal model of HD, we observed progressive and cell-autonomous nuclear accumulation of mhtt aggregates in MSNs. Surprisingly, unlike the mouse model expressing mhtt-exon1 in all the neurons in the brain, the striatal model lacks significant locomotor deficits and striatal neuropathology including gliosis and dark degenerating neurons. Electrophysiological findings from acutely dissociated MSNs revealed a cell-autonomous deficit in N-methyl-d-aspartate (NMDA) receptor sensitivity to Mg 2+ , a deficit also present in other mouse models of HD. In conclusion, this study provides the first in vivo genetic evidence that pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of HD, and suggests a ''two-hit'' hypothesis in which both cell-autonomous toxicity and pathological cell-cell interactions are critical to HD pathogenesis.

Multiple pathways contribute to the pathogenesis of Huntington disease

Huntingtin-protein interactions and the pathogenesis of Huntington's disease.

Complex Pathogenesis and Therapeutic Strategies

Huntington’s Disease: Complex Pathogenesis and Therapeutic Strategies

Huntingtin and Its Role in Neuronal Degeneration.

Pathological Cell-Cell Interactions Elicited by a Neuropathogenic Form of Mutant Huntingtin Contribute to Cortical Pathogenesis in HD Mice

Huntingtin Processing in Pathogenesis of Huntington Disease.

Huntingtin and Huntington’s Disease

Huntington's Disease: Molecular Basis of Pathology and Status of Current Therapeutic Approaches.

Huntingtin Interacting Proteins and Pathological Implications

Essential sequence of the N-terminal cytoplasmic localization-related domain of huntingtin and its effect on huntingtin aggregates

Accumulation of N-terminal Mutant Huntingtin in Mouse and Monkey Models Implicated As a Pathogenic Mechanism in Huntington's Disease

Pathological Cell-Cell Interactions Are Necessary for Striatal Pathogenesis in a Conditional Mouse Model of Huntington's Disease.

A Huntingtin-Associated Protein Enriched in Brain with Implications for Pathology

N-Terminal Mutant Huntingtin Associates with Mitochondria and Impairs Mitochondrial Trafficking

Inhibiting the ubiquitin-proteasome system leads to preferential accumulation of toxic N-terminal mutant huntingtin fragments.

Subcellular Clearance and Accumulation of Huntington Disease Protein: A Mini-Review.

Transgenic Animal Models for Study of the Pathogenesis of Huntington&rsquo;s Disease and Therapy

Polyglutamine Protein Trafficking and Neurodegeneration

Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy.

Progress in studies of gene therapy for Huntington's disease